Navigation Links
Building Support for a New Product Through Effective Internal Disease State Communication
Date:7/29/2011

CHAPEL HILL, N.C., July 29, 2011 /PRNewswire/ -- New pharmaceutical products - particularly those that are first-in-class, socially sensitive or treat a previously unknown condition - require not only external disease state communication but also internal communication to win support in the marketplace. Companies launching a product for a new or relatively unknown condition must acquaint the public as well as employees with the new disease before introducing a new product to treat it.

One step that companies have used to do this effectively is to "brand" the disease state or condition well before launch. Branding the condition highlights the need for a new drug to treat it and aids the process of professional education and discussion. Leading biopharma companies have employed naming and communication strategies before introducing first-in-class therapies for new or socially sensitive conditions like erectile dysfunction, social phobia, PMS, panic attack, insomnia, restless legs, overactive bladder, HIV and fibromyalgia.

A Best Practices, LLC benchmarking report, Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products, examines how companies communicate at the brand and disease state levels in order to educate employees internally and build a consistent, credible external message surrounding new products.

Built around qualitative information from a series of executive interviews and quantitative data from an in-depth survey that drew 32 top biopharma companies, this 67-page study details how to implement the type of well-timed and well-targeted communications strategies essential for a new product's market entry. Pharmaceutical, biotech and medical device managers and executives who supervise or interact with brand communications or new product development teams will be able to use this research to understand how and when veteran brand leaders introduce disease state information internally to win employee support of a new product.

The study spells out 10 key best practices culled from in-depth interviews with benchmark participants, who were involved in pre-launch, internal communication for Viagra, Gardasil, Prozac and many other successful brands. 

Key topics covered in this research include:

  • Ten best practices for internal disease state communication excellence
  • Effective communication channels & use of new communication technologies
  • Timing of communication activities by product development phase
  • Advantages & disadvantages of employee message segmentation
  • Tracking internal message effectiveness
  • Preventing sensitive-information leaks
  • Using KOLs to influence employees
  • Needs creation marketing tactics

To learn more about this report, including information about the research participants, key findings and sample best practices, please download a complimentary excerpt and study overview at: http://www3.best-in-class.com/rr1101.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For more than 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
2. Building a New and Better Ankle
3. Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting
4. Express Scripts Announces Plan to Build Fourth Building at Headquarters Campus
5. Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti
6. C&J Industries Completes Phases I and II of Building Expansion
7. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
8. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
9. EntreMed Raises $20 Million to Support Clinical Development Program
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, ... steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, a ... the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and ...
(Date:5/23/2017)... Santa Rosa, California (PRWEB) , ... May 23, ... ... population health management (PHM) technology and a 2017 Best in KLAS category winner, ... an advantageous market position to extend and enhance its technology platform and product ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... By all ... underway in Sonoma County. While officials call for diligence, asking homeowners to scout for ... at potential health concerns. Along with the annoying buzz of mosquitos is the buzz ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For ... the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at its ... LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment to ...
Breaking Medicine News(10 mins):